This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EffRx Pharmaceuticals SA
Drug Names(s): effervescent alendronate, EX101, Avalent, Steovess
Description: EX101 is an effervescent formulation of alendronate (Fosamax) formulated for more convenient dosing and reduced GI side effects. EX101 is administered in half the volume of water (120 ml) compared with the dosing recommendation for the tablet, and the soluble form means there is no tablet to lodge in the esophagus. There is also significantly reduced stomach acidity after dosing with EX101.
EffRx and Merck
In May 2006, EffRx announced that it entered into a worldwide exclusive license agreement with Merck & Co., granting EffRx a license to a number of patents related to effervescenttechnology in the bisphosphonate area. Financial terms were notdisclosed.
EffRx and Nycomed (Takeda)
In January 2009, EffRx and Nycomed announced that they signed a licensing deal for EX101 for the treatment of osteoporosis. Under the terms of agreement EffRx will receive from Nycomed upfront and milestone payments up to $59m. EffRx will in addition be granted double-digit royalties on future sales of EX101. Nycomed will also sponsor the necessary additional studies required for marketing approval. The licensing deal includes Europe, Russia, The Middle East, North Africa, Latin America and Canada.
In March 2009, EffRx and Nycomed announced that they signed an expansion of territories in their licensing deal for EX101 for the treatment of osteoporosis. Under...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc. Mission Pharmacal Company Hikma Pharmaceuticals plc
Additional information available to subscribers only: